Document:

Exhibit 4.1

 

AMENDMENT

 

This Amendment (“Amendment”)
is entered into as of June ___, 2016, by and between Aethlon, Inc., a Nevada corporation (the “Company”), and
the undersigned Subscriber (the “Subscriber”), which is one of the investors listed on the Schedule of Subscribers
(“Schedule of Subscribers”) attached to that certain Subscription Agreement between the Company and the
investors listed on the Schedule of Subscribers (the “Subscribers”) dated November 6, 2014, as amended (the
“SA”; all capitalized terms used and not defined herein are used as defined in the Notes, as amended (as defined
in the SA)) with reference to the following facts:

 

A.The Maturity
Date of the Notes was June 1, 2016, and the Company desires to have the Maturity Date extended to July 1, 2017.

 

B.In consideration
thereof, the Subscribers have requested various revisions to the Notes and the Warrants (for purposes of clarification, the defined
term “Warrant” refers to the Warrants issued in November 2014) as set forth below.

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, this Amendment will become effective upon execution and delivery of this Amendment
and a substantially identical Amendment (other than the identity of the Subscriber and Principal Amount of the Notes) of the other
Subscriber, and the Company and the Subscriber hereby agree as follows:

 

1.Amendment to
the Note and Warrant.

 

a. The Principal Amount
of the Note is hereby increased to $_____________ in the aggregate to include all accrued and unpaid interest thereon through June
15, 2016 and the Extension Fee as defined below. The increase in the principal amount is memorialized in an allonge to each Note,
the form of which is attached hereto as Exhibit A.

 

b. Maturity Date as
set forth in the preamble of the Note shall be defined as “July 1, 2017”.

 

c. The Conversion Price
in paragraph 2.1(b) of the Note shall be amended to state “$5.00, subject to adjustment as described herein”.

 

d. The Purchase Price
in paragraph 2.1(b) of the Warrant shall be amended to state “$5.00, subject to adjustment as described herein”.

 

2. Extension Fee
and Warrants. In consideration of the extension of the Maturity Date set forth in paragraph 1.b. above, the Company shall pay
the Subscriber a fee of Eighty Thousand Dollars ($80,000.00) (the “Extension Fee”), which shall be added to the principal
amounts as set forth in paragraph 1.a. above, $___________ of which shall be payable to __________________ and $___________ of
which shall be payable to __________________. The Company shall also issue, contemporaneously with the full execution and delivery
of this Amendment, warrants to purchase 30,000 shares of its common stock at an exercise price of $5.00 per share and terms otherwise
identical to the Warrants as follows: _______ warrants to __________________ and _______ warrants to __________________.

 

    	 	1	 

     

    

 

 

3.Acknowledgments.
The Company hereby confirms and agrees that except with respect to the amendments set forth in paragraphs 1 above, the Note and
Warrant remain in full force and effect as originally written.

 

4. Effectiveness
of Amendment. This Amendment shall only be effective upon the execution and delivery of this Amendment and the execution and
delivery of substantially identical Amendments by the other Subscriber. For purposes of determining the holding period under Rule
144 as promulgated under the Securities Act of 1933 with regard to the Note, the Warrant and any shares of Company common stock
to be issued upon conversion of the Note or exercise of the Warrant, the parties acknowledge and agree that the Subscriber shall
be deemed to have held the Note and Warrant from the date of initial issuance notwithstanding the existence of this Amendment and
the Consent and Waiver dated as of the date hereof.

 

5.Disclosure.
On or before 8:30 a.m., New York City time, on June __, 2016, the Company shall file a Current Report on Form 8-K describing the
terms of the transactions contemplated by this Amendment and the other substantially identical Amendments signed by other Subscribers
in the form required by the 1934 Act and attaching the form of waiver as an exhibit to such filing ((including all attachments),
the "8-K Filing"). From and after the issuance of the 8-K Filing, the Subscriber shall not be in possession of
any material, nonpublic information received from the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, affiliates or agents that is not disclosed in the 8-K Filing. In addition, effective upon the issuance of the 8-K Filing,
the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or
agents, on the one hand, and any of the Subscriber or any of its affiliates, on the other hand, shall terminate. The Company shall
not, and shall cause each of its Subsidiaries and its and each of their respective officers, directors, affiliates, employees and
agents, not to, provide any Subscriber with any material, nonpublic information regarding the Company or any of its Subsidiaries
from and after the date hereof without the express prior written consent of such Subscriber. To the extent that the Company, any
of its Subsidiaries or any of their respective officers, directors, affiliates employees or agents delivers any material, non-public
information to any Subscriber without such Subscriber’s consent, the Company hereby covenants and agrees that such Subscriber
shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors,
affiliates, employees or agents with respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, affiliates, employees or agents not to trade on the basis of, such material, non-public information. The Company understands
and confirms that the Subscriber will rely on the foregoing representations in effecting transactions in securities of the Company.

 

    	 	2	 

     

    

 

6.Independent
Nature of Subscriber Obligations and Rights. The obligations of the Subscriber under this Amendment are several and not joint
with the obligations of any other Subscriber, and the Subscriber shall not be responsible in any way for the performance of the
obligations of any other Subscriber under any other Amendment. Nothing contained herein or in any other Amendment, and no action
taken by the Subscriber pursuant hereto, shall be deemed to constitute the Subscriber and other Subscribers as a partnership, an
association, a joint venture or any other kind of entity, or create a presumption that the Subscriber and other Subscribers are
in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Amendment
or any other Amendment and the Company acknowledges that the Subscribers are not acting in concert or as a group with respect to
such obligations or the transactions contemplated by this Amendment or any other Amendment. The Company and the Subscriber confirm
that the Subscriber has independently participated in the negotiation of the transactions contemplated hereby with the advice of
its own counsel and advisors. The Subscriber shall be entitled to independently protect and enforce its rights, including, without
limitation, the rights arising out of this Amendment or, any other Amendment, and it shall not be necessary for any other Subscriber
to be joined as an additional party in any proceeding for such purpose.

 

7.No Third Party
Beneficiaries. This Amendment is intended for the benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

8.Amendments.
No provision of this Amendment may be amended other than by an instrument in writing signed by the Company and the Required Subscribers.

 

9.Further Assurances.
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Amendment and the consummation of the transactions contemplated hereby.

 

10.Notice.
Whenever notice is required to be given under this Amendment, unless otherwise provided herein, such notice shall be given in accordance
with Section 9(f) of the SA.

 

11.Successors
and Assigns. This Amendment shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns.

 

12.Capitalized
Terms. Capitalized terms used herein and not otherwise defined herein shall have the respective meaning set forth in the Note.

 

[Signature Pages Follow]

 

 

 

 

 

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF, each
undersigned and the Company have caused their respective signature page to this Amendment to be duly executed as of the date first
written above.

 

	 	 	 	COMPANY:
	 	 	 	 
	 	 	 	AETHLON MEDICAL, INC.
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	By:	

	 	 	 	 	Name:
	 	 	 	 	Title:
	 	 	 	 	 

 

 

 

 

 

 

 

 

 

 

 

    	 	4	 

     

    

 

IN WITNESS WHEREOF, each undersigned
and the Company have caused their respective signature page to this Amendment to be duly executed as of the date first written
above.

 

 

	 	 	SUBSCRIBER:

	 	 	 	 
	 	 	 	 
	 	 	[SUBSCRIBER]              
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	By: 	 
	 	 	 	Name: 
	 	 	 	Title: 

 

 

 

 

 

 

 

 

 

 

 

    	 	5Exhibit 4.2

 

ALLONGE TO CONVERTIBLE PROMISSORY NOTE

 

Allonge to that certain Convertible Promissory
Note attached hereto as Exhibit 1 and made a part hereof in the original principal amount of $_____________ dated November
6, 2014 (“Note”), from Aethlon Medical, Inc., as Borrower, to the order of _____________, as Lender ("Allonge").

 

Borrower and Lender agree that the Convertible
Promissory Note shall be revised as follows:

 

1.The term “Principal Amount” set forth
in the preamble to the Note is amended to read _______________________ Dollars ($______________). With respect to the original
principal amount of the Note of $_____________, the date of issuance is deemed to be November 6, 2014; with respect to the principal
amount of the Note of $____________, which is attributable to accrued and unpaid interest thereon on the original principal amount
of the Note, the date of issuance is deemed to be the date of accrual of such interest; and with respect to the principal amount
of the Note of $_____________, which was deemed due and owing as of the date of this Allonge, the date of issuance is deemed to
be the date of this Allonge.

 

2.The term “Maturity Date” as set forth
in the preamble to the Note is amended to read July 1, 2017.

 

3.The term “Conversion Price” as set forth
in paragraph 2.1(b) of the Note is amended to read $5.00, subject to amendment as described in the Note.

 

This Allonge is intended to be attached
to and made a permanent part of the Note.

 

Dated this ____ day of June, 2016.

 

 

 

 

	BORROWER:	LENDER:
	 	 
	Aethlon Medical, Inc.	 
	 	 
	 	 
	
        

        By:   James B. Frakes                                              

        Name: James B. Frakes

        Title: Chief Financial Officer
	
        By: _______________________________

        Name:

        Title:

 

 

 

 

    	 	1	 

     

    

 

 

 

 

EXHIBIT 1

 

 

 

Promissory Note

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]